Strength in numbers: The Latest Research in Near Infrared Light at Top Institutions
This technology is developed and licensed to Niraxx by the Massachusetts General Hospital.
Meet our Scientific Advisory Board Members & Researchers
Dr. Paolo Cassano
Dr. Cassano is an Assistant Professor in Psychiatry at Harvard Medical School, and Director of Photobiomodulation at the Massachusetts General Hospital Center for Anxiety and Traumatic Stress Disorders and Depression and Clinical Research Program. Dr. Cassano has over 10 years of experience in treatment of depressive disorders with low level laser therapy and brain bioenergetics.
Dr. Michael R. Hamblin
Niraxx Scientific Advisory Board Member and Principal Investigator at the Wellman Center for Photomedicine at Massachusetts General Hospital.
Dr. Maurizio Fava
Niraxx Scientific Advisory Board Member and Founder of Massachusetts General Hospital’s Depression Clinical and Research Program (DCRP).
Click the Links Below to See Our Original Research:
Around the Web
Related articles from publications around the web.
“At Mass. General, Paolo Cassano… is working on one of several pilot studies nationwide of transcranial infrared light therapy [which is] believed to decrease inflammation and oxidative stress in the brain as well as increase the formation of neurons.”
“Cassano thinks light therapy could provide a groundbreaking new tool for depression treatment — one that is affordable, without side effects and more immediate than medication.”
“New research at Massachusetts General Hospital is showing that it may be able to treat severe depression with the use of specialized light and without medication.”
“Exposure to a light that isn’t visible to the naked eye may be the next breakthrough treatment for depression. Massachusetts General Hospital psychiatrist Paolo Cassano, MD, PhD, and other researchers at MGH and elsewhere, are seeing encouraging results in studies of near-infrared light—the light closest on the spectrum to visible light.”